These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 26129925)

  • 1. Somatostatin analogues improve health-related quality of life in polycystic liver disease: a pooled analysis of two randomised, placebo-controlled trials.
    Neijenhuis MK; Gevers TJ; Nevens F; Hogan MC; Torres VE; Kievit W; Drenth JP
    Aliment Pharmacol Ther; 2015 Sep; 42(5):591-8. PubMed ID: 26129925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data.
    Gevers TJ; Inthout J; Caroli A; Ruggenenti P; Hogan MC; Torres VE; Nevens F; Drenth JP
    Gastroenterology; 2013 Aug; 145(2):357-65.e1-2. PubMed ID: 23665274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement: A Randomized Clinical Trial.
    Hogan MC; Chamberlin JA; Vaughan LE; Waits AL; Banks C; Leistikow K; Oftsie T; Madsen C; Edwards M; Glockner J; Kremers WK; Harris PC; LaRusso NF; Torres VE; Masyuk TV
    Clin J Am Soc Nephrol; 2020 Sep; 15(9):1267-1278. PubMed ID: 32843370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial.
    Gevers TJ; Hol JC; Monshouwer R; Dekker HM; Wetzels JF; Drenth JP
    Liver Int; 2015 May; 35(5):1607-14. PubMed ID: 25369108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.
    van Keimpema L; Nevens F; Vanslembrouck R; van Oijen MG; Hoffmann AL; Dekker HM; de Man RA; Drenth JP
    Gastroenterology; 2009 Nov; 137(5):1661-8.e1-2. PubMed ID: 19646443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease.
    van Aerts RMM; Kievit W; D'Agnolo HMA; Blijdorp CJ; Casteleijn NF; Dekker SEI; de Fijter JW; van Gastel M; Gevers TJ; van de Laarschot LFM; Lantinga MA; Losekoot M; Meijer E; Messchendorp AL; Neijenhuis MK; Pena MJ; Peters DJM; Salih M; Soonawala D; Spithoven EM; Visser FW; Wetzels JF; Zietse R; Gansevoort RT; Drenth JPH;
    Gastroenterology; 2019 Aug; 157(2):481-491.e7. PubMed ID: 31022403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alkaline phosphatase predicts response in polycystic liver disease during somatostatin analogue therapy: a pooled analysis.
    Gevers TJ; Nevens F; Torres VE; Hogan MC; Drenth JP
    Liver Int; 2016 Apr; 36(4):595-602. PubMed ID: 26481454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.
    Hogan MC; Masyuk TV; Page LJ; Kubly VJ; Bergstralh EJ; Li X; Kim B; King BF; Glockner J; Holmes DR; Rossetti S; Harris PC; LaRusso NF; Torres VE
    J Am Soc Nephrol; 2010 Jun; 21(6):1052-61. PubMed ID: 20431041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-acting somatostatin analogue treatments in autosomal dominant polycystic kidney disease and polycystic liver disease: a systematic review and meta-analysis.
    Griffiths J; Mills MT; Ong AC
    BMJ Open; 2020 Jan; 10(1):e032620. PubMed ID: 31924636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of somatostatin analogues on liver volume and quality of life in polycystic liver disease: a meta-analysis of randomized controlled trials.
    Garofalo C; Capuano I; Pennino L; De Gregorio I; Riccio E; Provenzano M; Crocetto F; Buonanno P; Pandolfo SD; Andreucci M; Pisani A
    Sci Rep; 2021 Dec; 11(1):23500. PubMed ID: 34873228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating health-related quality of life in patients with polycystic liver disease and determining the impact of symptoms and liver volume.
    Wijnands TF; Neijenhuis MK; Kievit W; Nevens F; Hogan MC; Torres VE; Gevers TJ; Drenth JP
    Liver Int; 2014 Nov; 34(10):1578-83. PubMed ID: 24313956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial.
    Caroli A; Perico N; Perna A; Antiga L; Brambilla P; Pisani A; Visciano B; Imbriaco M; Messa P; Cerutti R; Dugo M; Cancian L; Buongiorno E; De Pascalis A; Gaspari F; Carrara F; Rubis N; Prandini S; Remuzzi A; Remuzzi G; Ruggenenti P;
    Lancet; 2013 Nov; 382(9903):1485-95. PubMed ID: 23972263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of disease severity markers on quality of life in autosomal dominant polycystic kidney disease: a systematic review, meta-analysis and meta-regression.
    Neijenhuis MK; Kievit W; Perrone RD; Sloan JA; Erwin P; Murad MH; Gevers TJG; Hogan MC; Drenth JPH
    BMC Nephrol; 2017 May; 18(1):169. PubMed ID: 28545401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease.
    Pisani A; Sabbatini M; Imbriaco M; Riccio E; Rubis N; Prinster A; Perna A; Liuzzi R; Spinelli L; Santangelo M; Remuzzi G; Ruggenenti P;
    Clin Gastroenterol Hepatol; 2016 Jul; 14(7):1022-1030.e4. PubMed ID: 26844873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lanreotide Reduces Liver Volume, But Might Not Improve Muscle Wasting or Weight Loss, in Patients With Symptomatic Polycystic Liver Disease.
    Temmerman F; Ho TA; Vanslembrouck R; Coudyzer W; Billen J; Dobbels F; van Pelt J; Bammens B; Pirson Y; Nevens F
    Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2353-9.e1. PubMed ID: 26073493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial.
    Chrispijn M; Gevers TJ; Hol JC; Monshouwer R; Dekker HM; Drenth JP
    J Hepatol; 2013 Jul; 59(1):153-9. PubMed ID: 23499726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease.
    Gevers TJ; Chrispijn M; Wetzels JF; Drenth JP
    BMC Nephrol; 2012 Apr; 13():17. PubMed ID: 22475206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The long-term outcome of patients with polycystic liver disease treated with lanreotide.
    Chrispijn M; Nevens F; Gevers TJ; Vanslembrouck R; van Oijen MG; Coudyzer W; Hoffmann AL; Dekker HM; de Man RA; van Keimpema L; Drenth JP
    Aliment Pharmacol Ther; 2012 Jan; 35(2):266-74. PubMed ID: 22111942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatostatin analog therapy for severe polycystic liver disease: results after 2 years.
    Hogan MC; Masyuk TV; Page L; Holmes DR; Li X; Bergstralh EJ; Irazabal MV; Kim B; King BF; Glockner JF; Larusso NF; Torres VE
    Nephrol Dial Transplant; 2012 Sep; 27(9):3532-9. PubMed ID: 22773240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatostatin, estrogen, and polycystic liver disease.
    Everson GT; Helmke SM
    Gastroenterology; 2013 Aug; 145(2):279-82. PubMed ID: 23806538
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.